Skip to main content
Clive Page

Professor Clive Page

Professor of Pharmacology

Research interests

  • Pharmacology

Biography

Clive Page is a Professor of Pharmacology, King’s College London and Director of The Pulmonary Pharmacology Unit, King’s College London. Clive’s main research interests are in the pharmacology of inflammation and respiratory disease and he has published over 250 scientific papers. Clive was the co-founder and previous Chairman of the Board of Verona Pharma plc, an AIM listed Company developing new drugs for the treatment of Respiratory Diseases. He is a Non Executive Director of Babraham Biotechnology Ltd, as well as being a Trustee of the Babraham Institute in Cambridge and a Non Executive Director of the Board of ImmunoRegulation Ltd, PreP Biopharma and EpiEndo.

Clive started his early career in the Pharmaceutical Industry at Sandoz Ltd, Basel, Switzerland and regularly consults to both the Pharmaceutical and Biotech Industry.  Clive has previously held Non Executive Board positions at Cardiome in Canada and Stirling Products Ltd in Perth, Australia. Clive is a recent former Chairman of the Animal Science Group of the Society of Biology and has contributed widely to the public debate about the use of animals in Research. He was awarded the Society of Biology President’s Medal in 2012 for an outstanding contribution to the life sciences over the previous year.   He is a Fellow of the Royal Society of Biology and an Honorary Fellow and President Elect of the British Pharmacological Society.  In 2017, Clive was awarded an OBE for Services to Pharmacology

    Research

    Untitled design (9)
    Drug Discovery

    The Drug Discovery Group brings together scientific expertise in a broad range of areas, from medicinal chemistry to systems biology and pharmacology.

    AMR thumbnail
    Antimicrobial Research Theme

    Antimicrobial Research Theme

    News

    Low-cost drug Heparin effective and safe treatment for COVID-19

    Heparin, a widely available and affordable drug, has found to limit lung damage when inhaled by COVID-19 patients.

    covid-patient

      Research

      Untitled design (9)
      Drug Discovery

      The Drug Discovery Group brings together scientific expertise in a broad range of areas, from medicinal chemistry to systems biology and pharmacology.

      AMR thumbnail
      Antimicrobial Research Theme

      Antimicrobial Research Theme

      News

      Low-cost drug Heparin effective and safe treatment for COVID-19

      Heparin, a widely available and affordable drug, has found to limit lung damage when inhaled by COVID-19 patients.

      covid-patient